Notice of the 2026 first extraordinary general meeting
Filed with HKEX · Stock code 2509 · · 2 pages · English
Summary by 6ix AI
This filing is a notice for the first extraordinary general meeting of Qyuns Therapeutics Co., Ltd. scheduled for a future date. The meeting will address ordinary resolutions including the approval of revised annual caps for connected transactions and the appointment of a new non-executive director. Shareholders must register their transfers by a specified deadline to be eligible to attend and vote at the meeting.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Qyuns Therapeutics Co., Ltd. on 6ix
Earlier from Qyuns Therapeutics
- (1) Continuing connected transactions in relation to the revision of annual caps for the QX001S framework agreement; (2) proposed appointment of director and determination of the director's remuneration; and (3) notice of the 2026 first extraordinary general meeting
- Announcement book closure period for extraordinary general meeting
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement phase III clinical study results of Oturkibart (QX005N) for treatment of prurigo nodularis presented as a late-breaking oral presentation at EADV 2026
- List of directors and their roles and functions
Later from Qyuns Therapeutics
- Form of proxy for the extraordinary general meeting to be held on Friday, November 13, 2026
- Documents on Display
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Voluntary announcement exclusive license agreement with caldera therapeutics for a preclinical bispecific antibody program targeting TL1A and IL-17
Follow Qyuns Therapeutics into a list and get an email when it puts out news.
Follow Qyuns Therapeutics